Innovative assets
- New broad-spectrum vaccines against Leptospirosis;
- Collection of virulent circulating Leptospira strains directly isolated from infected dogs;
- New genetic tools for Leptospira, insights into biology and virulence mechanisms of atypical bacteria;
- New software and services offers for bacterial protective candidatesselection and antigen design;
- Rationally designed extraction reagents based on chemistry of nativemembrane proteins;
- Optimized host/vector couplesfor recombinant expression of membrane proteins
Highlights
5 Job creation, 7 student trainees
8 Equipment Investissements, 1 laboratory upgrades, 1 informatics server
1 Prototype of collaborative data sharing system, new reagents and screening approaches for enrichment of service offer, 1 development of new combo vaccine
2 Provisional patents filed, 1 ongoing. 2 accepted Publications, 3 in preparation. 2 posters, 1 Oral presentation at international conference. 1 award
7 press releases
Actual results
Innovative Assets
Detail: - New broad-spectrum vaccines against Leptospirosis - Collection of virulent circulating Leptospira strains directly isolated from infected dogs - New genetic tools for Leptospira, insights into biology and virulence mechanisms of atypical bacteria
Highlights
Detail: 5 Job creation, 7 student trainees 8 Equipment Investissements, 1 laboratory upgrades, 1 informatics server 1 Prototype of collaborative data sharing system, new reagents and screening approaches for enrichment of service offer, 1 development of new combo vaccine 2 Provisional patents filed, 1 ongoing. 2 accepted Publications, 3 in preparation. 2 posters, 1 Oral presentation at international conference. 1 award 7 press releases
Products & Services on the market
Number: 3
Detail: => 1 collaborative data sharing system developed by Genostar ; => 1 new reagent synthesis solution proposed by Calixar for protein purification ; => 1 screening approach for protein expression solubility and refolding proposed by PX'Therapeutics
Patents
Number: 3
Detail: - Provisional patent on usage of mutant attenuated in virulence as vaccine candidate (I. pasteur) - Provisionnal patent on the identification of new cross protective antigens identified in WP2. (consortia). - Ongoing filing on the usage of a second vi
Scientific publications
Number: 2
Detail: - Infect Immun. 2015 Aug 83(8) 3061-73.Pathogenic Leptospira interrogans exoproteins are primarily involved in heterotrophic processes.Eshghi A, Pappalardo E, Hester S, Thomas B, Pretre G, Picardeau M. - Infect Immun. 2015 Aug 17. accepted manusccript Le
Job creation in France
Number: 5
Job creation in Auvergne-Rhône-Alpes
Number: 2
Detail: Calixar, VetagroSup
Phd
Number: 1
Detail: Merial / I Pasteur Cifre subvention Célia Fontana
Communication in international congress
Number: 3
Detail: Gordon conference Biologie of spirochetes poster, January 2014 1 Oral presentation and 1 poster at Euopean Leptospirosis meeting, April 2015
Others (awards, new projects, certifications, partenerships, turnover increase, press releases, etc.)
Number: 9
Detail: Obtainment of the « Prix de biologie Alfred Kastler » award in June 2015, Submission for sanofi R&D awards, July 2015
+ 7 press releases
Perspectives
Set-up of a new R&D project :
possible project on human applications, immunology characterization. To be defined depending on the results od covalpeot dring the next few months
Preclinical assay realization :
WP4 advancement (evaluation of antigen candidates effiicacy)
Clinical trial realization :
once a candiate antigen ahs been idenitfied in the hamsters, studies in the target host (dog) will be conducted. Possible application to cattles
Product marketing :
merial initiated development of new combo vaccines incluing strains of WP1
